Format

Send to

Choose Destination
Lancet. 2009 Mar 21;373(9668):1033-40. doi: 10.1016/S0140-6736(09)60251-8.

Monoclonal antibodies for cancer immunotherapy.

Author information

1
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Abstract

Monoclonal antibodies are effective treatments for many malignant diseases. However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune responses. Such responses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cross-presentation of tumour antigens, or by triggering of the idiotypic network. Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer.

PMID:
19304016
PMCID:
PMC2677705
DOI:
10.1016/S0140-6736(09)60251-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center